Overview

• Researchers from Karolinska Institutet, Imperial College London, and Xiyuan Hospital have developed a urine test with an AUC of 0.92, significantly surpassing PSA tests' 0.65–0.75 range.
• The test uses spatial transcriptomics, pseudotime modeling, and machine learning to identify biomarkers indicating both the presence and severity of prostate cancer.
• Validated in nearly 2,000 patient samples, the test demonstrated exceptional diagnostic accuracy across urine, blood, and prostate tissue.
• Large-scale clinical trials under the UK’s £42 million TRANSFORM study aim to enrol 250,000–300,000 men over eight years to assess real-world effectiveness.
• The non-invasive and painless test offers the potential for at-home sampling, reducing unnecessary biopsies and enabling earlier, more precise diagnoses.